Archive for Guidelines

700 Doctors, Health Professionals, Including the American College of Lifestyle Medicine, Support Dietary Guidelines Message to Eat Less Meat, More Plants


Nashville, TN (PRWEB) May 26, 2015

Over 700 doctors, nutritionists, nurses, and public health professionals sent a letter to the secretaries of the U.S. Department of Agriculture and the U.S. Department of Health and Human Services urging them to embrace the 2015 Dietary Guidelines Advisory Committee’s recommendations to eat less meat and more plants for human health, economic prosperity, and our nation’s food security.

Leaders in lifestyle and preventive medicine signed the letter, including: Dr. David Katz, founding director of the Yale University Prevention Research Center and president of the American College of Lifestyle Medicine; Dr. Walter Willet, chair of the department of Nutrition at Harvard School of Public Health; and Dr. Dean Ornish, Clinical Professor of Medicine at the University of California, San Francisco.

In the letter, doctors and others “strongly endorse the Dietary Guidelines Advisory Committee’s recommendations to reduce consumption of animal foods and shift toward a more plant-based diet, both for the health of people and the planet.” The letter reaffirms the overwhelming scientific evidence for eating less meat and more plants clearly delineated by the committee.

One of the letter’s initial signers, Dr. David Katz, summarized why sustainability is important to nutrition: “If, in an age when we know that food and water shortages are clear and present dangers, we choose to ignore them in our dietary guidelines, then these are not dietary guidelines for Americans…They are, instead, dietary guidelines for the current generation of American adults, and at the obvious expense of all subsequent generations of American (and planetary) adults including of course, our children.”

Dr. Dean Ornish, known as the, “Father of Lifestyle Medicine,” and Clinical Professor of Medicine at the University of California, San Francisco added: “What’s good for you is also good for our planet. Although heart disease and diabetes kill more people each year worldwide than all other diseases combined, these are completely preventable and even reversible for at least 95% of people today by changing diet and lifestyle. Federal dietary guidelines as recommended by the scientific advisory committee would play a vital role in moving more people toward this goal.”

The letter further highlights how “a shift toward more plant-based foods will save the nation billions of dollars in health care costs and is essential to our nation’s health and economic prosperity,” because “chronic, preventable diseases are estimated to account for 75 percent of all healthcare costs.” Also, “heavy meat consumption, especially red and processed meat, is associated with increased risks of heart disease, diabetes and some cancers, while plant-based diets are associated with decreased risks of all three.”

In its comment submitted to the federal government, the American Public Health Association, representing over 30,000 public health professionals commended the Dietary Guidelines Advisory Committee for, “setting a priority of sustainability as an important component of the 2015 federal dietary guidance.” APHA praised the quality of the science relied upon by the committee and noted the committee’s conclusions on sustainability “… are important given the high level of resources used as inputs for food production in the U.S. – including 50 percent of the total U.S. land area, 80 percent of the fresh water and 10 percent of the fossil energy – and the importance of these resources for future food security.”

The inclusion of sustainability in the Dietary Guidelines recommendations has sparked tremendous interest, with more than 29,000 comments submitted to USDA and HHS by the May 8 deadline. The agencies plan to review comments and finalize the 2015 guidelines by the end of the year.

About the American College of Lifestyle Medicine (ACLM):

ACLM is a professional association of physicians and clinicians dedicated to the advancement and practice of Lifestyle Medicine as the foundation of a transformed and sustainable healthcare system. Lifestyle Medicine is a branch of evidence-based medicine in which comprehensive lifestyle changes (including nutrition, physical activity, stress management, social support and environmental exposures) are used to help prevent, treat and even reverse the progression of many chronic diseases by addressing their underlying causes. Visit http://www.lifestylemedicine.org, and learn more about ACLM’s annual conference, Lifestyle Medicine 2015, set for November 1-4, 2015 in Nashville, TN at http://www.lifestylemedicine2015.org.







More Diet Press Releases

Forbes: New Dietary Guidelines on Cholesterol Suggest that 50 Years of Medical Advice Was Wrong; The Center for the Biology of Chronic Disease (CBCD) Reviews the Report


Rochester, NY (PRWEB) February 17, 2015

Cholesterol in the diet or in the blood does not increase risk of heart disease, according to new research. In fact, shocking new cholesterol guidelines have been released by the Dietary Guidelines Advisory Committee based on this new data. There is a paradigm that has been accepted by the medical community regarding cholesterol since 1961. This standard stated that there is both “good” and “bad” cholesterol, and when an individual eats certain foods, it increases “bad” cholesterol in the blood, which in turn can lead to heart disease. This paradigm has been shattered by new research.

A summary of the committee’s December 2014 meeting says “Cholesterol is not considered a nutrient of concern for over consumption.” (See Harvard.edu, from February 12, 2015) (2) In other words, “You don’t need to worry about cholesterol in your food.” (2)

Professor Dan Rader said that “most of the cholesterol in our blood is not derived from our diets. Every cell in your body makes cholesterol. The old guidelines were based on a wrong assumption. We now know that cholesterol in the diet makes very little difference in terms of bad cholesterol in blood.” (1) He continued, saying that “the scandal here is that it’s taking so long for science to get incorporated into nutritional guidelines.” (1) Professor Rader is a professor of molecular medicine at the University of Pennsylvania.

But, if cholesterol is not the cause of heart disease, what is?

According to the CBCD, the answer is latent viruses.

More than one study has linked viruses to heart disease. In fact, both the human papillomavirus (HPV) and the varicella zoster virus (VZV) have been linked to cardiovascular disease. For instance, “Women infected with the human papillomavirus, or HPV, are two to three times as likely as uninfected women to have had a heart attack or stroke, according to a report published in The Journal of the American College of Cardiology.” (See the New York Times, from October 24, 2011) (3).

Another study found that VZV “is an independent risk factor for vascular disease.” (See the journal Neurology, from January 21, 2014) (4).

The Epstein Barr Virus (EBV), which is more common than HPV or VZV, is also linked to heart disease. “Looking at blood samples from 299 heart patients, researchers at Ohio State University found that those who had suffered a heart attack were the most likely to have inflammatory proteins circulating in their blood compared to patients with less acute symptoms. And having more of one of these proteins in the blood was linked to the presence of antibodies that signal a latent Epstein-Barr virus (EBV) reactivation.” (See News-Medical.net, from January 23, 2013) (6).

CMV is another common virus, which is linked to heart problems. “Cytomegalovirus was found to be the most common specific finding in immunocompetent patients (people with healthy immune systems) with fatal myocarditis.” (See Clinical Infectious Diseases, from March 1, 2005) (7).

“The new dietary recommendations, based on new research that shows no association between cholesterol and heart disease, should be no surprise to those who read Dr. Hanan Polansky’s book entitled ‘Microcompetition with Foreign DNA and the Origin of Chronic Disease.’” – Greg Bennett, CBCD

According to Dr. Polansky, the cause of heart disease, and other major diseases, is a latent infection with common viruses, including HPV, VZV, EBV, and CMV. Moreover, this theory also explains why the HPV study reports that “about 20 percent of patients with heart disease lack obvious risk factors (such as levels of saturated fat in the bloodstream).” (3)

How do latent viruses cause heart disease?

According to Dr. Hanan Polansky’s theory, these viruses are genetic parasites. In high concentrations, they microcompete with the human genes, “starve” these genes, and force them to behave as if they’ve been mutated, that is, to behave as if they are broken.

The Theory of Microcompetition is far-reaching. It applies to many viruses, many genes, and many diseases.

The CBCD encourages doctors and other healthcare professionals to read Dr. Polansky’s book, which predicted that viruses would be the cause of most major diseases, including heart disease, more than ten years ago. “The concept of Microcompetition (or Starved Gene) will change our approach in the study of chronic diseases and will furthermore give scientists a higher level of understanding in biology.” – Dr. Marc Pouliot, PhD (See more reviews of Dr. Polansky’s book at: http://www.cbcd.net/reviews.htm )

For a free copy of Dr. Polansky’s book, and to learn more about the Theory of Microcompetition, visit http://www.cbcd.net and click on free download.

References:

(1) Faye, F. “Why Eggs And Other Cholesterol-Laden Foods Pose Little Or No Health Risk.” Published on February 12, 2015. Forbes.com.

http://www.forbes.com/sites/fayeflam/2015/02/12/why-eggs-and-other-cholesterol-laden-foods-pose-little-or-no-health-risk/

(2) Skerrett, Patrick J. “Panel suggests that dietary guidelines stop warning about cholesterol in food.” Published on February 12, 2015. Harvard Health

http://www.health.harvard.edu/blog/panel-suggests-stop-warning-about-cholesterol-in-food-201502127713

(3) The New York Times – Troubles With Heart Are Linked to HPV. Published on October 24, 2011.

nytimes.com/2011/10/25/health/research/25theory.html?_r=0

(4) Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Published on January 21, 2014.

ncbi.nlm.nih.gov/pubmed/24384645

(5) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.U-s9ouOSz90

(6) News Medical – EBV reactivation can increase risk of heart disease.

Published on January 23, 2013

news-medical.net/news/20130123/EBV-reactivation-can-increase-risk-of-heart-disease.aspx

(7) Cytomegalovirus infection of the heart is common in patients with fatal myocarditis. Published on March 1, 2005.

ncbi.nlm.nih.gov/pubmed/15714413







SHAPE Task Force Applauds Recent Urgent Calls to Overhaul CVD Prevention Guidelines


Houston, TX (PRWEB) November 12, 2014

Leading preventive cardiologists and academic cardiovascular specialists from the Society for Heart Attack Prevention and Eradication (SHAPE), a non-profit organization advocating for early detection of future heart attack victims, endorse and applaud Dr. Steven Nissen’s urgent call to improve upon the existing inaccurate guidelines for detection and prevention of cardiovascular disease.

“We are delighted to hear Dr. Nissen and other well established physicians in the cardiology community call for revising existing guidelines” said Dr. PK. Shah, Chairman of SHAPE Scientific Advisory Board. “As many of you know, we have raised flags repeatedly since 2005 when we announced the SHAPE Guidelines and are looking forward to the much needed overhaul”.

After 10 years, as the field of cardiology anxiously awaited the NCEP IV Guidelines, the SHAPE Task Force was disappointed that several clinically important discoveries of the past decade were not incorporated in the AHA-ACC “Pooled Cohort” Guidelines. The Guidelines did not assign a proper role to the detection of subclinical atherosclerosis.

“In the past decade, a mountain of evidence has amassed supporting the superiority of screening for atherosclerosis over screening for risk factors of atherosclerosis, specially for detecting those with the highest near-term risk “the Vulnerable Patient”, however, most physicians are still treating their patients based on the outdated NCEP Guidelines” said Dr. Morteza Naghavi, Founder of SHAPE and Executive Chairman of the SHAPE Task Force. “It is disappointing that while other countries started incorporating atherosclerosis testing in their diagnostic algorithms, the US, where the research was largely done, lags in this regard. It is time for the US physicians to adopt practicing detection and treatment of atherosclerosis.”

The large, consistent body of evidence has demonstrated the value of using noninvasive imaging for early detection of atherosclerosis in its pre-symptomatic stage as recommended by the SHAPE Guidelines. While assessment of traditional risk factors such as high cholesterol and high blood pressure are important, it is now clear that the direct measurement of atherosclerosis, which measures the lifetime effects of known and unknown risk factors, is essential in identifying high risk individuals and improves the accuracy of their risk classification. SHAPE Guidelines focus on early detection of atherosclerosis whereas the existing guidelines focus on epidemiological risk factors of atherosclerosis which depict the statistical probability of developing atherosclerosis. The burden of atherosclerotic plaques predicts adverse events much more accurately than risk factors of atherosclerosis, particularly near-term events.

“We need to adopt Personalized Medicine to advance our patient care” said Dr. Daniel Berman, Chief of Nuclear Cardiology at Cedars Sinai Medical Center in Los Angeles and a leading member of SHAPE Task Force. “Treating patients for atherosclerosis without knowing if they have atherosclerosis, is a blind approach. The SHAPE Guidelines is a major step toward Personalized Medicine for prevention of atherosclerotic cardiovascular disease”

In 2009, the Appropriate Use Criteria considered coronary artery calcium scoring (CAC) “appropriate” for asymptomatic adults with an “Intermediate” global risk estimate, as well as those deemed lower risk with a family history of premature coronary heart disease. In 2010, the ACC/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults followed suit, elevating CAC and carotid plaque and intima-media thickness (CIMT) to Class IIa recommendations for cardiovascular risk assessment in asymptomatic adults at intermediate (10% to 20% 10-year) risk.

“The ACC’s Appropriate Use Criteria and 2010 Guidelines for Assessing Cardiovascular Risk was a big step forward. Unfortunately the new 2013 AHA/ACC Guidelines reversed some progress leading to significant over-treatment, especially in female populations” said Mathew Budoff, Professor of Medicine at UCLA and a leading member of SHAPE Task Force. “Today, there is absolutely no doubt that coronary calcium imaging predicts cardiovascular events better than all risk markers put together, including Framingham Risk Score, hs-CRP, and other new biomarkers”

The new AHA-ACC “Pooled” Guideline1, with its arbitrary change in the definition of High Risk in the primary prevention setting, is likely to result in marked overtreatment and undue “High Risk” labeling and statin therapy of many healthy women. For example, a 65year old non-smoking, non-diabetic, non-hypertensive woman with total cholesterol of 200 mg/dl and HDL of 49 mg/dl who lives an active life style would now be recommended statin therapy. In contrast, the same individual would be defined as Low Risk by the 2010 ACCF/AHA2 and NCEP Guidelines. More importantly, regardless of her cholesterol levels, if this female is tested negative for atherosclerosis, (absence of coronary calcium, absence of carotid plaques, or normal carotid wall thickness), she will be truly a low-risk individual and would not need statin therapy. The use of the new Guidelines also results in overestimation of the need for medications in certain subgroups of men. On the other side of the spectrum, high-risk individuals, men and women, with normal or borderline risk factors but a significant level of atherosclerotic plaques are overlooked as they would not qualify for intensive therapy. The existing AHA-ACC Guidelines address the PROBABILITY of coronary atherosclerotic disease and do not take into account whether such an individual has any evidence of subclinical atherosclerosis.

The Guidelines should no longer blindly favor intensive cholesterol lowering independent of atherosclerosis, but instead must target intensive therapy for those individuals with the highest burden of atherosclerotic “the Vulnerable Patient” who are expected to benefit the most from aggressive cholesterol-lowering and other interventions. The heightened awareness of possible statin induced hyperglycemia (diabetes mellitus) reinforces the need for more accurate and individualized risk assessment to insure that widespread drug therapy is appropriately implemented.

SHAPE is continuing its scientific quest for innovative approaches to heart attack prevention, and ultimately, eradication. As an educational nonprofit organization, SHAPE advocates only the most scientifically proven approach, independent of specific practices or procedures. SHAPE is actively supporting the Department of Health & Human Services Million Hearts™ initiative to prevent one million heart attacks and strokes over 5 years and encourages the DHHS authorities to consider national adoption of SHAPE Guidelines which is much more like to identify and save “the Vulnerable Patient” at risk of adverse events over 5 years.

In conclusion, given the large, consistent and growing body of evidence showing that testing for subclinical atherosclerosis is a more accurate method of predicting atherosclerotic cardiovascular events than testing for risk factors of atherosclerosis, the SHAPE Task Force applauds recent calls for revision of existing guidelines and respectfully urges the authorities at the American Heart Association and American College of Cardiology and effectively incorporate screening for atherosclerosis in determining risk and correspond the intensity of therapy to the burden of atherosclerosis.

****************************************

END

SHAPE encourages people to watch “Widowmaker”

http://www.widowmakerthemovie.com/

About the Society for Heart Attack Prevention and Eradication (SHAPE):

Originated from Houston, Texas and founded by Dr. Morteza Naghavi, SHAPE is a non-profit organization and is supported by leading cardiologists and cardiovascular researchers worldwide. The mission of SHAPE is to eradicate heart attack by championing new strategies for prevention while promoting the scientific quest for a cure such as “vaccine for atherosclerosis”. The immediate focus of SHAPE is on proper risk assessment of the asymptomatic individuals who are at risk of sudden cardiovascular events. SHAPE is committed to raising public awareness about revolutionary discoveries that are opening exciting avenues to prevent and ultimately eradicate heart attacks. Through educational programs presented to both medical professionals and the community, SHAPE raises awareness for the primary prevention of atherosclerotic cardiovascular disease. The vision of SHAPE is a world free from heart attack in the 21st century. Additional information is available on the organization’s website at http://www.shapesociety.org.

About the SHAPE Task Force:

Morteza Naghavi, M.D. – Executive Chairman

PK Shah, M.D. – Chair of Scientific Board

Erling Falk, M.D., Ph.D. – Chief of Editorial Committee

Members:

Arthur Agatston, M.D., Michael Blaha, M.D.,M.P.H., Daniel S. Berman, M.D., Matthew J. Budoff, M.D., Michael H. Davidson, M.D., Jim Ehrlich, M.D., Raimund Erbel, M.D., Erling Falk, M.D., Ph.D., Steven B. Feinstein, M.D., Craig Hartley, Ph.D., Harvey S. Hecht, M.D., Howard Hodis, M.D., Ioannis Kakadiaris, Ph.D., Sanjay Kaul, M.D., M.P.H., Iftikhar J. Kullo, M.D., Daniel Lane, M.D., Ph.D., Marge Lovell, R.N., Ralph Metcalfe, Ph.D., Morteza Naghavi, M.D., Tasneem Z. Naqvi, M.D., Khurram Nasir, M.D., Paolo Raggi, M.D., George P. Rodgers, M.D., John Rumberger, M.D., Ph.D., PK Shah, M.D., Leslee Shaw, Ph.D., David Spence, M.D., H. Robert Superko, M.D., Henrik Sillesen, M.D., Ph.D., Pierre-Jean Touboul, M.D.

Affiliation of Members of the SHAPE Task Force:

Arthur Agatston, M.D.

Associate Professor of Medicine,

University of Miami Miller School of Medicine

Founder and Director of the South Beach Diet and Heart Health Program

Miami, FL

Michael Blaha, M.D. M.P.H.

The Johns Hopkins

Ciccarone Center for the Prevention of Heart Disease

Baltimore, MD

Daniel S. Berman, M.D.

Director of Cardiac Imaging and of Nuclear

Cardiology at Cedars-Sinai

Los Angeles, CA

Matthew Budoff, M.D.

Vice President, Society of Atherosclerosis Imaging,

Professor of Medicine and Director of Preventive

Cardiology, UCLA Harbor

Los Angeles, CA

Michael H. Davidson, M.D.

FNLA Professor, Director of Preventive Cardiology, The University of Chicago Pritzker School of Medicine, Executive Medical Director,

Radiant Research

Chicago, IL

James Ehrlich, M.D.

Clinical Associate Professor

University of Colorado

Denver, CO

Raimund Erbel, M.D.

Professor of Medicine

University of Duisburg-Essen

Director of Department of Cardiology

West German Heart Center

Essen, Germany

Erling Falk, M.D., Ph.D.

Chief of SHAPE Guidelines Editorial Committee

Professor of Pathology and Cardiology

Aarhus University Hospital (Skejby)

Aarhus, Denmark

Steven B. Feinstein, M.D.

Professor of Medicine and Director of Echocardiograpy

Division of Cardiology, Rush University Medical Center

Chicago, IL

Craig Hartley, Ph.D.

Professor of Bioengineering

Baylor College of Medicine

Houston, TX

Harvey S. Hecht, M.D.

Professor of Medicine

Associate Director of Cardiac Imaging

The Mount Sinai Medical Center

New York, NY

Howard Hodis, M.D.

Professor of Cardiology and Preventive Medicine

Professor for Molecular Pharmacology and Toxicology

Director of Atherosclerosis Research Unit at the Division of Cardiovascular Medicine

Keck School of Medicine University of Southern California

Los Angeles, CA

Ioannis Kakadiaris, Ph.D.

Professor of Biomedical Computer Sciences

University of Houston<

Houston, TX

Sanjay Kaul, M.D., M.P.H.

Director, Cardiology Fellowship Training Program

Director, Vascular Physiology and Thrombosis Research

Laboratory at the Burns and Allen Research Institute

Cedars-Sinai Medical Center

Los Angeles, CA

Iftikhar J. Kullo, M.D.

Professor of Medicine

Division of Cardiovascular Disease

College of Medicine

Mayo Clinic

Rochester, MN

Roxana Mehran, M.D.

Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials, Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute

Mount Sinai School of Medicine

New York, NY

Ralph Metcalfe, Ph.D.,

Professor of Biomedical Engineering

University of Houston

Houston, TX

Morteza Naghavi, M.D.

Executive Chairman of SHAPE Task Force

President and CEO of MEDITEX

Houston, TX

Tasneem Z Naqvi, M.D. MMM

Professor of Medicine

Mayo College of Medicine

Director Echocardiography

Mayo Clinic

Arizona

Khurram Nasir, M.D.

Director,

Center for Prevention and Wellness Research,

Baptist Health South Florida,

Miami, Florida

Paolo Raggi, M.D.

Academic Director, Mazankowski Alberta Heart Institute

University of Alberta

Edmonton, AB

Canada

George P. Rodgers, M.D.

Preventive Cardiology and Wellness Center

Seton Heart Institute

Austin, TX

John Rumberger, M.D.

Director of Cardiac Imaging

The Princeton Longevity Center,

Princeton, NJ

PK Shah, M.D.

Chairman of SHAPE Scientific Committee

Chief of Cardiology and Director of Atherosclerosis Research, Cedars Sinai Medical Center

Professor of Medicine at UCLA School of Medicine

Los Angeles, CA

Leslee Shaw, Ph.D.

Professor of Cardiology

Outcome Research Center

Emory University

Atlanta, GA

Henrik Sillesen, M.D., D.MSc.

Director of HRP Study Carotid Examinations

Chairman, Department of Vascular Surgery Rigshospitalet

Professor of Surgery, University of Copenhagen

Copenhagen, Denmark

J. David Spence, M.D.

Professor of Neurology and Clinical Pharmacology,

University of Western Ontario

Director of Stroke Prevention & Atherosclerosis Research Centre,

Robarts Research Institute

London, ON

Canada

H. Robert Superko, M.D.

President – Cholesterol, Genetics, and Heart Disease Institute

Adjunct Professor

Mercer University School of Pharmaceutical Sciences

Atlanta, GA

Pierre-Jean Touboul, M.D.

Professor of Neurology

Department of Neurology and Stroke Center

AP-HP Bichat University Hospital

Neurology and Stroke Center

Paris, France